Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 66, Issue 4, 1999, Pages 436-441

  Pinter, M M ^a   Pogarell, O ^b   Oertel, W H ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Dopamine agonist; Parkinson's disease; Pramipexole

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; PRAMIPEXOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DREAMING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSKINESIA; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0033046354     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.66.4.436     Document Type: Article

References (17)

1. Mierau J, Schneider FJ, Ensinger H, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3, and D4 receptors. Eur J Pharmacol 1995;290:29-36.
2. Mierau J, Bechtel WD. SND 919 inhibits dopamine release in vivo and in vitro. Psychopharmacology 1988;96:338.
3. Robertson GS, Tham CS, Wilson C, et al. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 1993;264:1344-51.
4. Kreiss DS, Bergstrom BA, Gonzalez AM, et al. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol 1995;277:209-14.
5. Wright CE, Sisson TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-5.
6. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-47.
7. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA 1997;278:125-30.
8. Shannon KM, Bennett JP, Friedman JH, for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-8.
9. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995;45:225-30.
10. Liebermann A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of double-blind placebo-controlled, parallel-group study. Neurology 1997;49:162-8.
11. Gibb WRG, Lees AJ. The relevence of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
13. Fahn S, Elton RL, and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CDE, Calne D, et al, eds. Recent developments in Parkinson's disease, 2. Florham Park, NJ: MacMillian Healthcare Information, 1987:153-63.
14. Guttman M, and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-5.
15. Eisler T, Hall RP, Kalaver K, et al. Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology 1981;31:1368-70.
16. Demonet JF, Rostin M, Dueymes M, et al. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol 1986;9:200-1.
17. Melamed S, Braunstein GD. Bromocriptine and pleuropulmonary disease. Arch Intern Med 1989;149:258-9.